Argenx

Home » Argenx

Secondary

Argenx

Argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer.

Symbol

ARGX

Last Closing Price
$52.30

Shares
3,500,000

Effective Date
December 14, 2017

Underwriters
Cowen, Piper Jaffray

To view the prospectus for Argenx, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253